With Cost Study, Group Argues For OTC Benefit


A study by HECON Associates, a Maryland-based market research group, supports the claim that when prescription drugs become available over the counter, consumers face increased out-of-pocket costs.

The study focused on four drugs that recently became available over the counter. Researchers compared OTC costs with what consumers would pay in a mixed managed care/ indemnity plan (such as a private PPO), a typical HMO, and Maryland's Medicaid program. Sharp increases in out-of-pocket expenses were seen when products went to OTC status, due to the lack of an OTC drug benefit: As much as 113 percent in the managed care/indemnity plan, 233 percent in the HMO, and 9,000 percent for the Medicaid group, whose average pharmacy copayment was 13 cents.

Subscribe to Our Newsletters

Monthly table of contents

Be notified as each issue of Managed Care is available online.

Biweekly newsletter

Recent topics have included:

PTCommunity news

New drug approvals, clinical trials, drug management. Weekly.